Q-omics provides the consensus-scored MTREX profile across patient tissues and cancer cell-line models. MTREX expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, MTREX is differentially expressed in 11, with the highest sampling consensus in THCA. Additionally, MTREX protein abundance shows 35,450 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight KIRC, THCA, and GBM as cancer lineages where MTREX shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for MTREX — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes MTREX survival associations across molecular data types. MTREX RNA expression shows survival associations in the most cancer types (23), followed by mutation status (6) and mass-spec protein abundance (8). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible MTREX RNA expression–survival associations across cancer types. High MTREX expression shows unfavorable associations in OV, UVM, LIHC and KICH, but favorable associations in KIRC and READ. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for MTREX RNA expression.
This table summarizes MTREX tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11, while mass-spec protein shows differences in 10. The strongest signals are observed in THCA for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for MTREX. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. MTREX shows lower tumor expression in THCA and higher tumor expression in LIHC, COAD, STAD, LUAD and CHOL. The THCA box plot shows higher MTREX RNA expression in normal versus tumor tissue (log2 FC = −0.491, t-test p < 0.001).
This table shows molecular features associated with MTREX in patient tissues and cancer cell lines. In patient samples, MTREX shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, MTREX RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_SCLC, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Lymphoma and BREAST.
